What is Taiko Pharmaceutical Co.,Ltd.'s (4574.T) StockRank?

MoatMap's StockRank for Taiko Pharmaceutical Co.,Ltd. (4574.T) is 83/100, with a Strong Buy signal. This is a composite score combining Quality (71), Value (69), and Momentum (29) factor ranks across MoatMap's 20,000+ stock universe.

Does Taiko Pharmaceutical Co.,Ltd. have an economic moat?

Taiko Pharmaceutical Co.,Ltd. (4574.T) has a Quality factor score of 71/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Taiko Pharmaceutical Co.,Ltd. a buy, hold, or sell?

MoatMap's current signal for Taiko Pharmaceutical Co.,Ltd. (4574.T) is Strong Buy, based on a StockRank of 83/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Taiko Pharmaceutical Co.,Ltd. in?

Taiko Pharmaceutical Co.,Ltd. (4574.T) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Japan).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

4574.T

STRONG BUYREMOVE

Taiko Pharmaceutical Co.,Ltd. · Healthcare · Japan · $81M · Avg Vol: $180K/d

StockRank

P/E (TTM)

14.2x

ROE

20.1%

D/E

0.0x

Dividend %

5.4%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Taiko Pharmaceutical is a Japanese OTC drug manufacturer. It lacks a scalable global moat, has volatile earnings, and does not align with our high-conviction CDMO or healthcare themes.

COMPANY DESCRIPTION

Taiko Pharmaceutical Co., Ltd. manufactures and sells gastrointestinal medicines and infection control products, famous for its flagship antidiarrheal brand 'Seirogan.' The company also operates a growing infection prevention segment under the 'Cleverin' brand, utilizing chlorine dioxide technology to sanitize air and surfaces. Its competitive advantage is rooted in its dominant domestic market share in traditional OTC antidiarrheals and strong brand equity.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	32M	38M	39M	40M	8.3%
EPS	-0.70	-0.48	0.11	0.11	2.7%
Shares	44M	50M	51M	51M	+14.7%
Debt	24M	20M	14M	6M	-36.6%
Equity	50M	42M	50M	53M	1.9%
Op CF	-12M	-2M	2M	5M	124.9%
Inv CF	1M	7M	-31,259	887,761	—
Fin CF	-6M	10M	-7M	-8M	—

PRICE (1M)-8.2%

SMA 50SMA 200

$1.68

RSI (14)

61.1

52W High

$2.74

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

9.9%73.2

ROE

20.1%88.7

GP/Assets

125.0%97.8

Op. Margin

21.3%84.4

FCF/Assets

—N/A

Piotroski

—28.7

Int. Cover

50.0x91.5

D/E Ratio

0.00x93.8

Current Ratio

2.65x48.3

Value

P/E (TTM)

14.2x75.7

EV/EBITDA

0.9x61.8

P/FCF

—N/A

P/B

0.5x90.4

P/S

0.6x91.2

Div Yield

5.4%93.1

Momentum

52W High %

61%42.0

RS 6M

-48%23.8

SMA 50/200

0.96x50.1

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—5.9

Q Growth

-33%16.9

FUNDAMENTALS

Market Cap

$81M

P/E (Forward)

56.5x

Gross Margin

69.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 4574.T are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
4574.T	Taiko Pharmaceutical Co.,Ltd.(you)	$81M	83	STRONG BUY
9273.T	Koa Shoji Holdings Co.,Ltd.	$210M	84	STRONG BUY
4595.T	Mizuho Medy Co.,Ltd.	$207M	81	STRONG BUY
4577.T	Daito Pharmaceutical Co.,Ltd.	$218M	85	STRONG BUY
4512.T	Wakamoto Pharmaceutical Co.,Ltd.	$61M	45	HOLD
4886.T	ASKA Pharmaceutical Holdings Co.,Ltd.	$522M	90	STRONG BUY
4554.T	Fuji Pharma Co., Ltd.	$362M	98	STRONG BUY
4534.T	Mochida Pharmaceutical Co., Ltd.	$768M	81	STRONG BUY
4559.T	Zeria Pharmaceutical Co., Ltd.	$634M	95	STRONG BUY
4538.T	Fuso Pharmaceutical Industries,Ltd.	$109M	34	SELL

Peer medians: ROE 8.1% · P/E 15.6x · Gross margin 47.8%

Taiko Pharmaceutical Co.,Ltd. (4574.T) — Stock Score Summary

Taiko Pharmaceutical Co.,Ltd. (4574.T) has a MoatMap StockRank of 83/100 based on Quality (71/100), Value (69/100), and Momentum (29/100) factor scores. The current signal is STRONG BUY. Taiko Pharmaceutical is a Japanese OTC drug manufacturer. It lacks a scalable global moat, has volatile earnings, and does not align with our high-conviction CDMO or healthcare themes.

Key Financial Metrics

Price	$1.68
Market Cap	$81M
P/E (TTM)	14.15
P/E (Forward)	56.52
Price/Book	0.49
Return on Equity	20.1%
Return on Invested Capital	9.9%
Debt/Equity	0.41
Gross Margin	69.2%
Operating Margin	21.3%
Revenue Growth	15.9%
Dividend Yield	5.4%

Taiko Pharmaceutical Co.,Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Japan).

Frequently Asked Questions

What is Taiko Pharmaceutical Co.,Ltd.’s (4574.T) StockRank?: MoatMap’s StockRank for Taiko Pharmaceutical Co.,Ltd. (4574.T) is 83/100, with a Strong Buy signal. It is a composite of Quality (71), Value (69), and Momentum (29) factor ranks across MoatMap’s 20,000+ stock universe.
Does Taiko Pharmaceutical Co.,Ltd. have an economic moat?: Taiko Pharmaceutical Co.,Ltd. (4574.T) has a Quality factor score of 71/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Taiko Pharmaceutical Co.,Ltd. a buy, hold, or sell?: MoatMap’s current signal for Taiko Pharmaceutical Co.,Ltd. (4574.T) is Strong Buy, based on a StockRank of 83/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Taiko Pharmaceutical Co.,Ltd. in?: Taiko Pharmaceutical Co.,Ltd. (4574.T) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Japan).